Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline

[1]  M. Carrillo,et al.  Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. , 2000, Life sciences.

[2]  M. Naoi,et al.  Cell death of dopamine neurons in aging and Parkinson’s disease , 1999, Mechanisms of Ageing and Development.

[3]  J. Qi,et al.  L‐deprenyl potentiates NGF‐induced changes in superoxide dismutase mRNA in PC12 cells , 1998, Journal of neuroscience research.

[4]  S. Cohen,et al.  Sparing by Rasagiline (Tvp-1012) of Cholinergic Functions and Behavior in the Postnatal Anoxia Rat , 1998, Pharmacology Biochemistry and Behavior.

[5]  M. Naoi,et al.  (−)‐Deprenyl Protects Human Dopaminergic Neuroblastoma SH‐SY5Y Cells from Apoptosis Induced by Peroxynitrite and Nitric Oxide , 1998, Journal of neurochemistry.

[6]  D. Chuang,et al.  Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. , 1998, Molecular pharmacology.

[7]  T. Takeshima,et al.  Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor , 1998, Neuroreport.

[8]  P. Fürst,et al.  Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 andR-(−)-Deprenyl* , 1998, The Journal of Biological Chemistry.

[9]  W. Tatton,et al.  Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawal: Time Course and Modification by (−)-Deprenyl , 1998, The Journal of Neuroscience.

[10]  A. Lees,et al.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[11]  M. Naoi,et al.  An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.

[12]  Y. Agid,et al.  Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. , 1997, Histology and histopathology.

[13]  H. Moriwaki,et al.  Rapid loss in the mitochondrial membrane potential during geranylgeranoic acid-induced apoptosis. , 1997, Biochemical and biophysical research communications.

[14]  W. Tatton Modulation of gene expression rather than monoamine oxidase inhibition , 1996, Neurology.

[15]  J. Finberg,et al.  Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo , 1996, Journal of neurochemistry.

[16]  D. Chuang,et al.  Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Hubble,et al.  The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.

[18]  M. Youdim The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction , 1995, Acta psychiatrica Scandinavica. Supplementum.

[19]  D. Holland,et al.  (−)‐Deprenyl Reduces PC12 Cell Apoptosis by Inducing New Protein Synthesis , 1994, Journal of neurochemistry.

[20]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[21]  G. Engberg,et al.  Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  M. Youdim,et al.  TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B , 1981, British journal of pharmacology.

[23]  I. Fridovich,et al.  Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). , 1969, The Journal of biological chemistry.

[24]  R. F. Beers,et al.  A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. , 1952, The Journal of biological chemistry.

[25]  A. Kupsch,et al.  Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. , 1998, Journal of neural transmission. Supplementum.

[26]  Z. Speiser,et al.  Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. , 1998, Journal of neural transmission. Supplementum.

[27]  M. Youdim,et al.  Pharmacology and neuroprotective properties of rasagiline. , 1996, Journal of neural transmission. Supplementum.

[28]  M. Carrillo,et al.  (-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. , 1991, Life sciences.